Kornimate/medical-research-clean huggingface dataset:
efficacy of lidocaine versus placebo in palliative care patients with opioid-refractory cancer pain with neuropathic component: a multicenter, prospective, double-blind randomized placebo-controlled study.

Conditions: Cancer; Pain With Neuropathic Component

Summary: this is a multicenter, prospective, randomized, placebo-controlled, double-blind, two-parallel groups study comparing lidocaine (experimental group) to placebo (control group). the study protocol was elaborated using the recommendations of the consolidated standards of reporting trials (consort) statement.


Eligibility criteria:
inclusion criteria: * patient aged 18 years or older * patient suffering from cancer pain refractory to standard opiates (numeric pain intensity scale npis \>=4/10 after 24 hours of continuous intravenous morphine or oxycodone administration \[sor 2002, analgesics drugs for adults cancer nociceptive pain\]), regardless of the nature of the primary cancer\] * patient suffering from cancer neuropathic or mixed pain (dna survey score\> = 4 \[bouhassira 2004\]) * patient receiving palliative care as defined by french society of palliative and support care \[charte des soins palliatifs, 1996, act no. 99-477 of 9 june 1999 to guarantee the right of access to palliative care\] according to the definition of the world health organization (who) \[world health organization. who's pain ladder. http://www.who.int/cancer/palliative/painladder/en/. accessed december 9.2011\] * patient with histological diagnosis of cancer, locally advanced or metastatic disease * patient without curative cancer treatment, and with or without palliative anticancer treatment * patient hospitalized in a specific palliative care unit * patient with an estimated survival higher than 48 hours (physician estimation) patient providing written informed consent for participation prior to any study procedures. exclusion criteria: * patient with a known hypersensitivity to lidocaine * patient with a history of porphyria, arrhythmias, disorders of atrioventricular conduction requiring permanent pacing not yet realized, uncontrolled epilepsy, uncontrolled hypertension * patient with hematologic malignancy, abnormal renal, hepatic and cardiac functions * patient with a altered sleepiness (epworth scale score ≤ 16) * patient with altered cognitive function (telecom scale score\> 11) \[arsène 2000\] * patient not native french speaker patient defined as vulnerable subject (minor subject, pregnant or nursing woman, subject freedom deprived)

Keywords: cancer pain
plantarflexion reduces urgency and peak detrusor pressure in patients with detrusor overactivity

Conditions: Overactive Detrusor

Summary: the purpose of this study is to find out whether plantarflexion has an effect on the degree of urinary urgency and on the amplitude of detrusor contraction during filling cystometry in patients with detrusor overactivity (do).

patients with urodynamic do will be included in this study. during urodynamics, the mean peak detrusor pressures of each contraction will be documented and compared. at the beginning of the 2nd or 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor. following each wave, patients will be asked to grade the severity of the urgency by a visual analogue scale

Eligibility criteria:
inclusion criteria: all patients with urodynamic detrusor overactivity exclusion criteria: inability to perform plantarflexion due to mental or physical disability

Keywords: detrusor overactivity plantarflexion urgency
a study of shr-a1811 in subjects with ovarian cancer

Conditions: Ovarian Cancer

Summary: this is an open-label study to evaluate the safety and efficacy of shr-a1811 for injection in subjects with ovarian cancer.


Eligibility criteria:
inclusion criteria: 1. the subjects voluntarily joined the study and signed the informed consent forms (icf). 2. measurable disease, as defined by recist v1.1. 3. the eastern cancer cooperative group (ecog) performance status of 0 or 1. 4. life expectancy ≥ 12 weeks. exclusion criteria: 1. symptomatic, untreated or active central nervous system metastases. 2. have uncontrolled or severe cardiovascular disease. 3. with any active autoimmune disease or history of autoimmune disease. 4. patients with active hepatitis b or hepatitis c. 5. severe infections prior to initiation of study treatment. 6. patients with active tuberculosis.
reintroduction regimens after hepatitis during anti-tuberculosis treatment

Conditions: Hepatitis; Tuberculosis, Pulmonary

Summary: despite the availability of effective anti-tuberculosis agents that exist to treat this illness, hepatotoxicity during first-line drugs anti-tuberculosis medications (att) such as isoniazid (inh), rifampin (rif), and pyrazinamide (pza) is not uncommon and limit their use. there is no consensus on method of the reintroduction of anti-tb medications. the risk of reintroducing of a anti-tb medications could be hazardous. there are several differences between the guidelines from the ats, bts and the task force of the european respiratory society, the who and the international union against tuberculosis and lung disease about the methods of reintroducing of anti-tb medications. the investigators plan to do a prospective study to evaluate the outcome and safety of reintroduction of anti-tb medications after resolution of hepatitis during anti-tb treatment among tb patients in the investigators hospital.

tuberculosis (tb) remains a leading health problem in both developing and developed countries. despite the availability of effective chemotherapeutic agents that exist to treat this illness, hepatotoxicity during first-line drugs anti-tuberculosis medications (att) such as isoniazid (inh), rifampin (rif), and pyrazinamide (pza) is not uncommon and limit their use. in the case of confirmed moderate or severe drug-induced hepatotoxicity, treatment should be interrupted and reintroduced after the hepatotoxicity has resolved. there is no consensus on method of the reintroduction of anti-tb medications. the risk of reintroducing of a anti-tb medications could be hazardous. there are several differences between the guidelines from the ats, bts and the task force of the european respiratory society, the who and the international union against tuberculosis and lung disease about the methods of reintroducing of anti-tb medications. we plan to do a prospective study to evaluate the outcome and safety of reintroduction of anti-tb medications after resolution of hepatitis during anti-tb treatment among tb patients in our hospital.

Eligibility criteria:
inclusion criteria: * hepatitis during anti-tuberculosis treatment * hold rmp, inh and pza after hepatitis * age \>= 18 years old * hiv(-) * t-bilirubin \< 2.5 mg/dl * no allergy to rmp, inh and pza exclusion criteria: * liver cirrhosis, child b or c * pregnancy and breast feeding * life expectation \< 1 year
predictive analytics and clinical decision support to improve prep prescribing

Conditions: HIV

Summary: scale-up of hiv preexposure prophylaxis (prep) is a key strategy of the u.s. initiative to end the hiv epidemic, but healthcare providers lack tools to support prep discussions and prescribing for patients likely to benefit. this research will evaluate whether integrating automated tools into electronic health records to help providers efficiently and equitably identify potential candidates for prep, discuss prep, and prescribe prep can improve prep initiation and persistence in safety-net community health centers. it will achieve this by conducting a stepped-wedge trial of a decision support tool with an embedded hiv prediction model to identify patients likely to benefit from prep. the intervention will be delivered to healthcare providers in 16 community health centers within the national ochin network.


Eligibility criteria:
inclusion criteria: * delivery site saw at least 500 distinct patients in 2024 during in-person or telehealth visits * delivery site had at least 10 new hiv diagnoses or positive hiv screening tests in 2023 * delivery site provides primary care other than pediatrics, and the primary care department(s) were active on ochin epic as of 1/1/2023 exclusion criteria: * delivery site specializing in hiv or sti care * correctional facilities * mobile sites * school-based health center sites

Keywords: hiv prep pre-exposure prophylaxis prevention prediction model clinical decision support
three techniques in bioceramic apexification for necrotic immature incisors

Conditions: Immature Teeth; Periapical Lesion

Summary: the goal of this randomized clinical trial is to find the most effective bioceramic-based apexification procedures in children with immature necrotic maxillary incisors. the main questions they aims to answer are: * what is the best bioceramic apexification technique regarding the post-operative pain and the periapical healing ? * what is the best bioceramic apexification technique regarding the bioceramics extrusion and the required time ? participants will under gone bioceramic apexification procedures which root canal preparing, disinfecting, filling, and restoring. then, the patient will asked to come to follow-up appointments for clinical and radiological evaluations if there is a comparison group: researchers will compare bioceramic putty apical plugs, single cone gutta-percha with bioceramic sealer, and combination of bioceramic putty and sealer technique to find the best effective technique.


Eligibility criteria:
inclusion criteria: * patients with one or more maxillary incisors with an open apex root (defined as root which root canal size equal or larger than #80 k-file) and presented with pulp necrosis and radiographic evidence of chronic apical periodontitis and periapical radiolucency greater than 3 mm. exclusion criteria: * children with systemic diseases that compromised their general immune status. * uncooperative (definitely negative on the frankl's behavioral scale). * unrestorable incisors.

Keywords: post-operative pain periapical lesion healing bioceramic apexification
screening for crc using a mixed strategy of sigmoidoscopy and colonoscopy in average-risk population according to age

Conditions: Colorectal Cancer

Summary: background: primary screening with sigmoidoscopy would miss a substantial proportion of advanced proximal neoplasia (apn), but screening with universal colonoscopy is costly. the aim of this study is to assess the efficacy of mixed strategy which uses sigmoidoscopy for younger patients and colonoscopy for older patients. materials and methods: we analyzed an established database containing consecutive average-risk adults aged 50 or older who underwent screening colonoscopy as part of health check-up. we assessed the efficacy of mixed screening strategy using colonoscopy for persons aged at and above a certain cut-off age and sigmoidoscopy for persons aged below that age. those who underwent sigmoidoscopy initially would be referred for subsequent colonoscopy if distal sentinel lesion was detected.

because the prevalence of proximal colon cancer and apn was higher in older patients15, a greater proportion of advanced colonic neoplasia or cancer would be missed if colonoscopy was not performed for older patients. so if we develop a mixed strategy to offer sigmoidoscopy for younger patients and reserve colonoscopy for older patients, we might be able to detect more apn with fewer colonoscopic procedures. we aimed to determine an optimal cut-off age and choose an appropriate distal sentinel lesion for subsequent colonoscopy.

Eligibility criteria:
inclusion criteria: * only asymptomatic ethnic chinese subjects aged 50 years or older who underwent total colonoscopy were included in this study exclusion criteria: * persons with symptoms indicative of colorectal cancer, such as hematochezia, body weight loss, development of persistent abdominal pain or rectal pain, and a change in bowel habit, were excluded from this study. other exclusion criteria were: (1) past history of crc, colon polyps, or inflammatory bowel disease; (2) a history of screening tests, including fobt, sigmoidoscopy, colonoscopy, or barium studies within 5 years; (3) any first degree relative(s) with colon cancer; (4) criteria for hereditary nonpolyposis colorectal cancer, familial adenomatous polyposis, or other polyposis syndrome; (5) obvious anemia with hemoglobin level less than 10g/dl; (6) incomplete examination of entire colon, including poor colon preparation and failure to reach cecum.

Keywords: colorectal cancer screening colonoscopy
updated severity and prognosis score of pulmonary alveolar proteinosis

Conditions: Pulmonary Alveolar Proteinosis

Summary: by updating the chest hrct scoring criteria of patients with pulmonary alveolar proteinosis, a new and more perfect system for evaluating the severity of alveolar proteinosis will be established.

in past, investigators summarized a method that was the severity and prognosis of pulmonary alveolar proteinosis (spsp) to assess the severity and prognosis of patients with autoimmune pulmonary alveolar proteinosis (auto pap). the spsp included five aspects: smoking, symptom, pao2, chest ct score at specific levels (aortic arch, carina, pulmonary vein confluence, and superior septal level) and dlco %predicted. but the chest ct score only focused on range of lesions, and inaccurate. so, investigators plan to adopt new score which involves the assessing to range and density. in the new chest hrct score, we added the density score. the average density of the lesions at a particular level of the patient's chest hrct was measured by computer and classified into three degrees: mild (less than -400), moderate (greater than -400 and less than -100) and severe (greater than 100), denoted as 1 ', 2 'and3', respectively. the range score of lung opacity was estimated using a five-point scale: no opacity = 0; opacity involving \< 25% of a region of hemithorax = 1; 25-50% = 2; 50-75% = 3; and ≥ 75% = 4. the lesion score for each layer is equal to the density score multiplied by the range score. the chest hrct score was calculated by summing the lung opacity scores of the four representative regions of each hemithorax, and divided into several level: no opacity = 0; ≤10 = 1; 11 - 20 = 2; 21 - 30 = 3; 31 -40 = 4; \> 40 = 5. according to the new chest hrct score, the spsp will be updated to spsp ii. in this study, patients with auto pap from three centers (shanghai lung hospital, peking union medical college hospital and nanjing drum tower hospital) were enrolled to evaluate the severity of disease severity score (dss), spsp and spsp ii, respectively, to evaluate the pros and cons of different scores and their impact on prognosis. about 30 newly diagnosed auto pap patients were recruited, and were assess disease severity on the basis on spsp ii scores. according to spsp ii scores, appropriate treatment was used for the patients, who were followed up for 3 months.

Eligibility criteria:
inclusion criteria: * the patients had be diagnosed with autoimmune pulmonary alveolar proteinosis through pathology or bronchial alveolar lavage fluid (balf). * the patients are old than 18 year. * .every patient had a complete medical history, chest hrct, pulmonary function and arterial blood gas analysis. * the patients have high level antibody of gm-csf in serum or balf. exclusion criteria: * the patients had a congenital or secondary pulmonary alveolar proteinosis.
stretching exercises and temporomandibular disorders

Conditions: Temporomandibular Disorders

Summary: to compare the efficacy of global postural reeducation (gpr) with static stretching exercises (ss) in the treatment of women with temporomandibular disorders (tmd). physical therapy is of importance in the treatment of myogenic temporomandibular disorders (tmd). both stretching exercise and global posture reeducation are equally effective in the treatment of tmd.

purpose: to compare the efficacy of global postural reeducation (gpr) with static stretching exercises (ss) in the treatment of women with temporomandibular disorders (tmd). methods: a total of 24 subjects with tmd were randomized into two treatment groups: gpr, where therapy involved muscle global chain stretching, or ss, with conventional static stretching. eight treatment sessions lasting 40 minutes each (weekly) were performed. assessments were conducted at baseline, immediately after treatment end, and again two months later. measurements included pain intensity at the temporomandibular joint, headache, cervicalgia (visual analogue scale - vas) and teeth clenching. additionally, electromyographic activity and pain thresholds were measured at the masseter, anterior temporalis, sternocleidomastoid, and upper trapezius muscles. two-way analysis of variance (anova) with tukey post-hoc test was used for in-between group comparisons. significance level was 0.05.

Eligibility criteria:
inclusion criteria: * helkimo index iii, * myogenic tmd, and * presence of para-functional habits, such as: bruxism, teeth clenching, mouth-breathing and lip biting. exclusion criteria: * surgery or trauma in the orofacial region, * systemic or degenerative diseases, or * undergoing odontological, psychological, or physical therapy treatments.

Keywords: stretching pain
the study on the evaluation of acupuncture therapy on primary insomnia

Conditions: Primary Insomnia

Summary: through the recruition of outpatients who clinically meet the diagnostic criteria and inclusion criteria of pi, the acupuncture group adopts tiaoshen acupuncture, and the placebo acupuncture group adopts non-insertive acupuncture supported by the park device, and the pittsburgh sleep quality index (psqi) is used as the main index to evaluate the patients through the scale; subjective indicators like chalder 14-item fatigue scale, epworth sleepiness rating, self-rating anxiety scale (sas), self-rating depression scale (sds) and objective indicators like polysomnography (psg), heart rate variability (hrv) is regarded as a secondary index, and then evaluate the clinical efficacy of tiaoshen acupuncture on pi and explore its mechanism.


Eligibility criteria:
inclusion criteria: * conforming to the diagnostic criteria of traditional chinese and western medicine for chronic insomnia; * age range: 18-70 years old; * psqi score\>7 points; sas score \> 50 or sds score \> 53; * no communication and cognitive impairment; * no use or withdrawal of psychoactive drugs such as anti-anxiety within one month; ·no major physical diseases; * those who voluntarily accept the research content and can complete various scale evaluations, polysomnography monitoring and hrv; * sign an informed consent form prior to the start of the study. exclusion criteria: * those who do not meet the inclusion criteria; * persons with a history of severe mental illness, severe head injury, and significant disturbance of consciousness; * those with severe liver and renal insufficiency and bleeding tendencies; * alcoholism (liquor ≥ 100ml/day), smoking (≥ 15 cigarettes/day), drug abuse or taking psychotropic drugs; * people with other sleep disorders, such as sleep apnea hypopnea syndrome, paroxysmal sleeping sickness, and rem sleep behavioral disorders; * pregnant or nursing; * those with other major diseases and poor control; * other persons who are unwilling to sign informed consent.

Keywords: acupuncture primary insomnia rct
initial management in patients with differentiated thyroid cancer in the real world in china

Conditions: Differentiated Thyroid Cancer

Summary: * to find out the gap between real-world clinical practice and guideline recommendations in initial management of dtc patients * to observe the characteristics of patients who achieved and did not achieve tsh target value after one year follow-up * to assess response to initial therapy in patients who undergo total or near-total thyroidectomy and rai remnant ablation after one year follow-up (according to an modified dynamic risk stratification system) * to observe the recurrence status after one year follow-up

multi-center, prospective, registry study 2000 dtc patients undergo the first-time thyroidectomy and identified as intermediate or high risk of recurrence will be recruited. doctors can treat the patients based on disease conditions. investigators will record data which are related to study endpoints. primary endpoint(s): 1. proportion of patients who underwent total/near-total thyroidectomy 2. proportion of patients who were treated by 131i after undergoing total/near-total thyroidectomy 3. proportion of patients who achieved serum tsh target value 4. proportion of patients who did not achieve serum tsh target value although they were treated by tsh suppression therapy secondary endpoint(s): 1. time to achieve serum tsh target value 2. dosage of l-t4 for patients who achieved and did not achieve serum tsh target value 3. dosage of l-t4 per kilogram of body weight for patients who achieved and did not achieve serum tsh target value 4. proportion of excellent response/acceptable response/biochemical incomplete response/structural incomplete response to initial management in patients who undergo total or near-total thyroidectomy and rai remnant ablation after one year follow-up 5. recurrence rate after one year follow-up 6. aes related to l-t4 (or thyroid tablet)treatment

Eligibility criteria:
inclusion criteria: 1. patients who are diagnosed as dtc (the diagnosis should base on pre-operative examinations and post-operative pathology report) 2. patients who undergo the first-time thyroidectomy 3. patients who are identified as intermediate-risk or high-risk of recurrence after thyroidectomy (according to the recurrence risk stratification of chinese management guideline for patients with thyroid nodules and differentiated thyroid cancer published in 2012) 4. patients who have chinese nationality 5. patients who have signed an informed consent form exclusion criteria: 1. history of thyroid surgery 2. other malignant tumors 3. severe organ damage such as heart failure of new york heart association classes iii-iv, liverfailure, respiratory failure, renal failure, etc. 4. medical or psychological condition that would not permit the patient to complete the study or sign the informed consent 5. legal incapacity or limited legal capacity 6. unwilling to be followed up

Keywords: differentiated thyroid cancer the initial management